表紙
市場調查報告書

女性的低性慾障礙(HSDD):管線lie產品分析

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 268986
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
女性的低性慾障礙(HSDD):管線lie產品分析 Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020
出版日期: 2020年03月31日內容資訊: 英文 52 Pages
簡介

所謂低性慾障礙(HSDD)是指對性行為的興趣和慾望缺乏或不足的狀態。發病的要素有神經不安症,憂鬱症,雄激素缺乏症,及慢性腎衰竭和高催乳激素血症等慢性消耗性疾病等。治療方法有抗憂鬱症藥及荷爾蒙療法。

本報告提供女性的低性慾障礙(HSDD)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

女性的低性慾障礙(HSDD)概要

治療藥的開發

  • 開發中產品的概要
  • 開發平台:各企業
  • 開發中的產品:各企業

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Apricus Biosciences, Inc.
  • Emotional Brain BV
  • GlaxoSmithKline Plc
  • Palatin Technologies, Inc.
  • Valeant Pharmaceuticals International Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12058IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyper-prolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 6, 1 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Female Hypoactive Sexual Desire Disorder - Overview
  • Female Hypoactive Sexual Desire Disorder - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
  • Better Life Pharmaceuticals Inc
  • Dare Bioscience Inc
  • Emotional Brain BV
  • EndoCeutics Inc
  • Fabre-Kramer Pharmaceuticals Inc
  • Ivix Ltd
  • Kuhnil Pharmaceutical Co Ltd
  • S1 Biopharma Inc
  • Female Hypoactive Sexual Desire Disorder - Drug Profiles
  • (buspirone hydrochloride + testosterone) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (sildenafil citrate + testosterone) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • gepirone hydrochloride ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KI-1120 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PGSN-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • prasterone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sildenafil citrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SIP-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Female Hypoactive Sexual Desire Disorder - Dormant Projects
  • Female Hypoactive Sexual Desire Disorder - Discontinued Products
  • Female Hypoactive Sexual Desire Disorder - Product Development Milestones
  • Featured News & Press Releases
  • Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
  • Dec 11, 2019: Dare Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
  • Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
  • Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
  • Jun 17, 2019: Dare Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal disorder
  • Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
  • Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
  • Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference
  • Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
  • Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
  • Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials
  • Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials
  • Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
  • Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
  • May 01, 2015: Emotional Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Ivix Ltd, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2020
  • Female Hypoactive Sexual Desire Disorder - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020